Thiazolidinediones Diagnostic criteria: 2 trials applied the WHO 1999 criteria (FPG ≥ 7.0 mmol/L and/or a 2‐hour glucose ≥ 11.1 mmol/L after a 75 g OGTT) (Jin 2009; Zeng 2013). No medical association recommended the cut‐off points applied in Maji ... · people at increased risk for developing type 2 diabetes
Summary of findings table for metformin showed no clear difference in thiazolidinediones Diagnostic criteria: 2 trials applied the WHO… compared with diet and exercise or another antidiabetic drug (low certainty).
1 finding from 1 review
Thiazolidinediones · people at increased risk for developing type 2 diabetes
2 findings from 1 review
Intervention not reported
Non‐fatal macrovascular outcomes 1. Composite a. Intervention vs metformin [1a. 6 months to 4 years] b. Intervention vs thiazolidinediones [1b. 52 weeks to 4 years] c. Intervention vs meglitinide [1c. 12 months to 15 months]2. Non‐fatal myocardial... · participants with type 2 diabetes mellitus
The intervention may leads to lower non‐fatal macrovascular outcomes 1. Composite a. Intervention vs… (low certainty).
1 finding from 1 review
RR 0.67 [0.48, 0.93]
1 study · 3 participants
Low
Intervention not reported
Cancer a. Intervention vs thiazolidinediones [52 weeks to 4 years] b. Intervention vs insulin [6 years to 10 years] · participants with type 2 diabetes mellitus
The intervention showed no clear difference in cancer a. Intervention vs thiazolidinediones [52 weeks to 4 years]… (low certainty).
1 finding from 1 review
Intervention not reported
Health‐related quality of life a. Intervention vs thiazolidinediones [12 months] b. Intervention vs insulin [6 years] c. Intervention vs alpha‐glucosidase inhibitors [12 months] · participants with type 2 diabetes mellitus
1 finding from 1 review
Intervention not reported
Adverse events 1. All adverse events 2. Drop‐outs due to adverse events Interventions vs thiazolidinediones [1. 6 months to 12 months] [2. 24 weeks to 52 weeks] · participants with type 2 diabetes mellitus
The intervention may leads to lower adverse events 1. All adverse events 2. Drop‐outs due to adverse… (low certainty).
1 finding from 1 review
RR 0.88 [0.78, 0.99]
1 study · 3 participants
Low
Intervention not reported
All‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs incretin‐based control [d. 52 weeks to... · participants with type 2 diabetes mellitus
The intervention showed no clear difference in all‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4… (low certainty).
1 finding from 1 review
Intervention not reported
Cardiovascular mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs meglitinide [d. 12 months to 17 m... · participants with type 2 diabetes mellitus
The intervention showed no clear difference in cardiovascular mortality a. Intervention vs metformin [a. 24 weeks… (low certainty).
1 finding from 1 review
All‐cause mortality
It is very uncertain whether summary of findings of metformin monotherapy for adults with type 2… changes all‐cause mortality compared with thiazolidinediones (very low certainty).
1 finding from 1 review
SAEs
It is very uncertain whether summary of findings of metformin monotherapy for adults with type 2… changes serious adverse events (SAE) compared with thiazolidinediones (very low certainty).
1 finding from 1 review
Health‐related quality of life
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality
It is very uncertain whether summary of findings of metformin monotherapy for adults with type 2… changes cardiovascular mortality (CVM) compared with thiazolidinediones (very low certainty).
1 finding from 1 review
Non‐fatal MI
1 finding from 1 review
Non‐fatal stroke
1 finding from 1 review
End‐stage renal disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found